Gynecol Oncol. 2015 Dec 23. pii: S0090-8258(15)30223-7. doi: 10.1016/j.ygyno.2015.12.020. [Epub ahead of print]
- Efficacy and safety of olaparib monotherapy in germline BRCA1/2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapy.
Domchek Susan M, et al. Gynecologic oncology 2015 12 (From HuGE Literature Finder)
Efficacy and safety of olaparib monotherapy in germline BRCA1/2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapy.
Domchek SM1, Aghajanian C2, Shapira-Frommer R3, Schmutzler RK4, Audeh MW5, Friedlander M6, Balmaña J7, Mitchell G8, Fried G9, Stemmer SM10, Hubert A11, Rosengarten O12, Loman N13, Robertson JD14, Mann H14, Kaufman B3.
Abstract
OBJECTIVE:
The efficacy and safety of olaparib, an oral poly(ADP-ribose) polymerase (PARP) inhibitor, was investigated in a subgroup of patients with germline BRCA1/2 mutated (gBRCA1/2m) advanced ovarian cancer who had received ≥3 prior lines of chemotherapy. Primary data from this Phase II study (Study 42, ClinicalTrials.govNCT01078662) have been reported previously.
METHODS:
RESULTS:
CONCLUSION:
Copyright © 2015. Published by Elsevier Inc.
KEYWORDS:
BRCA1/2 mutation; Olaparib; Ovarian cancer; Phase II
- PMID:
- 26723501
- [PubMed - as supplied by publisher]
No hay comentarios:
Publicar un comentario